Close Menu

NEW YORK – Biotechnology company Freenome and ADC Therapeutics, an oncology drug discovery and development company, announced today that they have signed a biomarker development agreement.

The companies will use Freenome's multiomics platform for early cancer detection to identify patients who are most likely to respond to treatment with ADC's antibody drug conjugate loncastuximab tesirine (ADCT-402). ADC is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The General Data Protection Regulation has slowed some data sharing with non-European researchers as they find ways to comply with the law, ScienceInsider reports.

A bioethicist from Abertay University uses a utilitarian approach to justify genetically modifying the human germline, the BBC reports.

The US has upgraded its network of public health labs to provide whole-genome sequencing to track antibiotic-resistant bacteria, Quartz reports.

In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings,  and more.